Please login to the form below

Not currently logged in
Email:
Password:

Relovair

This page shows the latest Relovair news and features for those working in and with pharma, biotech and healthcare.

Breathing easier

While there are several therapies currently in late-stage clinical trials for COPD — including aclidinium bromide (Eklira, Almirall Prodesfarma/Forest Laboratories), vilanterol/fluticasone furoate (Relovair, GSK), andolast (Rottapharm Madaus) and

Latest news

  • GSK increases Theravance investment

    The centrepiece of the partnership is a phase III product for asthma called Relovair (fluticasone furoate/vilanterol trifenatate), which is a potential once-daily therapy combining a long-acting beta2 agonist

  • Phase III trials begin for Relovair

    The first asthma patient has commenced treatment with GlaxoSmithKline's Relovair in a phase III programme. ... The first asthma patient has commenced treatment with GlaxoSmithKline's (GSK) Relovair in a phase III programme.

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Interview: Deepak Khanna, ABPI Interview: Deepak Khanna, ABPI

    Referencing a 'real-world' study into GlaxoSmithKline's (GSK) Relovair in Salford, he says: “We have a good example where the NHS partnered with three companies to focus on COPD.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics